Bibliografía
1. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Informe de posicionamiento terapéutico de tofacitinib (Xeljanz®) en colitis ulcerosa. IPT 40/2019. AEMPS; 2019.
2. Vermeire S, Su C, Lawendy N, et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING Trial. J Crohns Colitis 2021;15(7):1130-41. DOI: 10.1093/ecco-jcc/jjaa249
3. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II - An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160(5):1570-83. DOI: 10.1053/j.gastro.2020.12.031
4. Muñoz F. Nuevas dianas terapéuticas en la enfermedad inflamatoria intestinal. Enferm Inflamatoria Intest al Día 2017;16:138-50. DOI: 10.1016/j.eii.2017.04.001
5. Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol 2016;310(3):G155-62. DOI: 10.1152/ajpgi.00311.2015
6. López-Sanromán A, Esplugues JV, Domenech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol 2021;44(1):39-48. DOI: 10.1016/j.gastre.2020.04.007
7. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica Xeljanz. AEMPS; 2022. Disponible en: https://cima.aemps.es/cima/dochtml/ft/1171178003/FT_1171178003.html
8. Casellas F, Guinard Vicens D, García-López S, et al. Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations. Eur J Gastroenterol Hepatol 2020;32(12):1514-22. DOI: 10.1097/MEG.0000000000001885
9. Edel Y, Sagy I, Pokroy-Shapira E, et al. A cross-sectional survey on the preference of patients with rheumatoid arthritis for route of administration of disease-modifying anti-rheumatic drugs: oral target-specific versus parenteral biologic. IMAJ 2020;22(3):154-9.
10. Hagelund LM, Elkjaer Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis - Results from a survey study. Curr Med Res Opin 2020;36(5):771-9. DOI: 10.1080/03007995.2020.1716704
11. Louder AM, Singh A, Saverno K, et al. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 2016;9(2):84-93.
12. Dassopoulos T, Cohen RD, Scherl EJ, et al. Ulcerative colitis care pathway. Gastroenterology 2015;149(1):238-45. DOI: 10.1053/j.gastro.2015.05.036
13. Sands BE, Armuzzi A, Marshall JK, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020;51(2):271-80. DOI: 10.1111/apt.15555
14. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376(18):1723-36. DOI: 10.1056/NEJMoa1606910
15. Sandborn WJ, Peyrin-Biroulet L, Quirk D, et al. Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis. Clin Gastroenterol Hepatol 2022;20(8):1821-30.e3.
16. Colombel JF, Osterman MT, Thorpe AJ, et al. Maintenance of remission with tofacitinib therapy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2022;20(1):116-25.e5.
17. Panes J, Vermeire S, Dubinsky MC, et al. Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: results from the OCTAVE clinical trials. J Crohns Colitis 2021;15(11):1852-63. DOI: 10.1093/ecco-jcc/jjab065
18. Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 2019;21(1):89. DOI: 10.1186/s13075-019-1866-2
19. Sandborn W, Dhaens G, Sands B, et al. S777 tofacitinib for the treatment of ulcerative colitis: up to 7.8 years of safety data from global clinical trials. Am J Gastroenterol 2021;116:S360-S. DOI: 10.14309/01.ajg.0000776640.47467.7e
20. Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatol Ther 2020;7(3):553-80. DOI: 10.1007/s40744-020-00209-4
21. Sandborn WJ, Peyrin-Biroulet L, Sharara AI, et al. Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status. Clin Gastroenterol Hepatol 2022;20(3):591-601.e8.
22. Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2022;55(4):464-78.
23. Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 2018;24(10):2258-65. DOI: 10.1093/ibd/izy131
24. Ministerio de Sanidad, Consumo y Bienestar Social. Vacunas y programa de vacunación. Herpes zóster. Recomendaciones de vacunación actuales acordadas en el Consejo Interterritorial del Sistema Nacional de Salud. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/vacunas/ciudadanos/zoster.htm
25. Grupo de trabajo de vacunación frente a herpes zóster de la Ponencia de Programa y Registro de Vacunaciones. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad; 2021. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/docs/HerpesZoster_RecomendacionesVacunacion.pdf
26. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Notas de seguridad. Xeljanz (tofacitinib): nuevas precauciones de uso. AEMPS; 2022. Disponible en: https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/seguridad-1/2021-seguridad-1/xeljanz-tofacitinib-nuevas-precauciones-de-uso/
27. Sandborn WJ, Panés J, D’Haens GR, et al. Tofacitinib for the treatment of ulcerative colitis: up to 6.8 years of safety data from global clinical trials. Am J Gastroenterol 2020;115:S353-S4. DOI: 10.14309/01.ajg.0000704860.70861.89
28. Sands BE, Colombel JF, Ha C, et al. Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for cardiovascular risk and patient management. Inflamm Bowel Dis 2021;27(6):797-808. DOI: 10.1093/ibd/izaa227
29. Sands BE, Long MD, Reinisch W, et al. Tofacitinib for the treatment of ulcerative colitis: analysis of nonmelanoma skin cancer rates from the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2022;28(2):234-45. DOI: 10.1093/ibd/izab056
30. Panes J, Gisbert JP. Efficacy of tofacitinib treatment in ulcerative colitis. Gastroenterol Hepatol 2019;42(6):403-12. DOI: 10.1016/j.gastre.2019.03.012
31. Dubinsky MC, Peyrin-Biroulet L, Melmed GY, et al. Efficacy of tofacitinib in patients with ulcerative colitis by prior tumor necrosis factor inhibitor treatment status: results from OCTAVE induction and maintenance studies. Disponible en: https://eventscribe.com/2017/wcogacg2017/ajaxcalls/PosterInfo.asp?efp=S1lVTUxLQVozODMy&PosterID=114733&rnd=5.004501E-02
32. Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA Registry. J Crohns Colitis 2021;15(1):35-42. DOI: 10.1093/ecco-jcc/jjaa145
33. Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis 2020;14(10):1385-93.
34. Biemans VBC, Sleutjes JAM, de Vries AC, et al. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 2020;51(9):880-8. DOI: 10.1111/apt.15689
35. Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol 2020;18(10):2179-91e6. DOI: 10.1016/j.cgh.2020.01.008
36. Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis 2022;28(1):32-40. DOI: 10.1093/ibd/izab011
37. Hernández Martínez A, Navajas Hernández P, Martín Rodríguez MDM, et al. Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia. Rev Esp Enferm Dig 2022;114(9):516-21.
38. Sicilia B, Garcia-Lopez S, Gonzalez-Lama Y, et al. GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol. 2020 Aug;43 Suppl 1:1-57.
39. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J Crohns Colitis. 2021 Oct. [Epub ahead of print]
40. Hanauer S, Panaccione R, Danese S, et al. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-47.
41. Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol. 2021 Oct;19(10):2112-20 e1.
42. Kotwani P, Terdiman J, Lewin S. Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience. J Crohns Colitis. 2020 Jul 30;14(7):1026-8.
43. Uzzan M, Bresteau C, Laharie D, et al. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. Aliment Pharmacol Ther. 2021 Aug;54(3):312-9.
44. D'Amico F, Parigi TL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631.
45. Argollo M, Gilardi D, Peyrin-Biroulet C, et al. Comorbidities in inflammatory bowel disease: a call for action. The lancet Gastroenterology & hepatology. 2019 Aug;4(8):643-54.
46. Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/xeljanz-2.
47. Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD open. 2020;6(3):e001374.
48. Jamilloux Y, El Jammal T, Vuitton L, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019 Nov;18(11):102390.
49. Damsky W, Peterson D, Ramseier J, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021 Mar;147(3):814-26.
50. Silfen A, Cohen N, Traboulsi C, et al. Tofacitinib Therapy is Effective for Arthralgias Associated with Active Inflammatory Bowel Disease. Poster presentations: Clinical: Therapy and Observation 2021. Available from: https://www.ecco-ibd.eu/publications/congress-abstracts/item/p455-tofacitinib-therapy-is-effective-for-arthralgias-associated-with-active-inflammatory-bowel-disease.html.
51. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017 Oct 19;377(16):1537-50.
52. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525-36.
53. Nash P, Coates LC, Fleischmann R, et al. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatology and therapy. 2018 Dec;5(2):567-82.
54. van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Aug;76(8):1340-7.
55. Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015 Oct;173(4):949-61.
56. Papp KA, Krueger JG, Feldman SR, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. J Am Acad Dermatol. 2016 May;74(5):841-50.
57. Ruperto N, Brunner HI, Zuber Z, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J. 2017 Dec 28;15(1):86.
58. Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI insight. 2016 Sep 22;1(15):e89776.
59. Kong X, Sun Y, Dai X, et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis. 2021 Aug 6.
60. Khanna D, Bush E, Nagaraja V, et al. Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis-Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial. Arthritis & rheumatology. 2019;71(10)
61. Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct;77(4):675-82 e1.
62. Orfaly VE, Kovalenko I, Tolkachjov SN, et al. Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol. 2021 Aug;46(6):1082-5.
63. Salmon Olavarria P, Rubio Iturria S, Nantes Castillejo O. Tofacitinib, a useful option for the treatment of pyoderma gangrenosum in an ulcerative colitis patient. Rev Esp Enferm Dig. 2021 Oct;113(10):733-4.
64. Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015 Sep;73(3):395-9.
65. Chen Z, Wang X, Ye S. Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease. N Engl J Med. 2019 Jul 18;381(3):291-3.
66. Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA dermatology. 2016 Aug 1;152(8):944-5.
67. Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. N Engl J Med. 2018 Dec 27;379(26):2540-6.
68. Zhu KJ, Yang PD, Xu Q. Tofacitinib Treatment of Refractory Cutaneous Leukocytoclastic Vasculitis: A Case Report. Front Immunol. 2021;12:695768